Q4 Review | Suven Life Sciences’ Q4 Report Card & FY24 Projections

#Q4WithBQ | Suven Life Sciences' revenue contracts and loss widens on an yearly basis. Can company see improved performance in FY24?In conversation with Chairman & CEO Venkat Jasti. #BQLive